Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Funda Meric-Bernstam

Showing results (531-540 of 643) with videos related to

Pageof 65
Sort By:
Oncotarget|November 3, 2016
Clinical outcomes based on multigene profiling in metastatic breast cancer patientsReva K Basho, Debora de Melo Gagliato, Naoto T Ueno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2022
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I TrialFunda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, et al.
Clinical Genitourinary Cancer|August 7, 2021
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy TrialsOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experienceAllen M Chen, Funda Meric-Bernstam, Kelly K Hunt, et al.
JCI Insight|April 20, 2017
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patientsVivek Subbiah, Muhammad Rizwan Khawaja, David S Hong, et al.
Molecular Cancer Therapeutics|March 11, 2014
Concordance of genomic alterations between primary and recurrent breast cancerFunda Meric-Bernstam, Garrett M Frampton, Jaime Ferrer-Lozano, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2019
Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversionAna Lluch, Ana M González-Angulo, David Casadevall, et al.
The Lancet. Oncology|November 18, 2022
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion studyFunda Meric-Bernstam, Muralidhar Beeram, Erika Hamilton, et al.
Cancer Medicine|February 13, 2025
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell CarcinomaOmar Alhalabi, Mohamed A Gouda, Denái R Milton, et al.
American Journal of Clinical Pathology|October 22, 2015
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencingSinchita Roy-Chowdhuri, Debora de Melo Gagliato, Mark J Routbort, et al.
Pageof 65

Showing results (531-540 of 643) with videos related to

Sort By:
Pageof 65
Oncotarget|November 3, 2016
Clinical outcomes based on multigene profiling in metastatic breast cancer patientsReva K Basho, Debora de Melo Gagliato, Naoto T Ueno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2022
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I TrialFunda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, et al.
Clinical Genitourinary Cancer|August 7, 2021
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy TrialsOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experienceAllen M Chen, Funda Meric-Bernstam, Kelly K Hunt, et al.
JCI Insight|April 20, 2017
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patientsVivek Subbiah, Muhammad Rizwan Khawaja, David S Hong, et al.
Molecular Cancer Therapeutics|March 11, 2014
Concordance of genomic alterations between primary and recurrent breast cancerFunda Meric-Bernstam, Garrett M Frampton, Jaime Ferrer-Lozano, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2019
Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversionAna Lluch, Ana M González-Angulo, David Casadevall, et al.
The Lancet. Oncology|November 18, 2022
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion studyFunda Meric-Bernstam, Muralidhar Beeram, Erika Hamilton, et al.
Cancer Medicine|February 13, 2025
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell CarcinomaOmar Alhalabi, Mohamed A Gouda, Denái R Milton, et al.
American Journal of Clinical Pathology|October 22, 2015
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencingSinchita Roy-Chowdhuri, Debora de Melo Gagliato, Mark J Routbort, et al.
Pageof 65